Fig. 3: Association of 4 weeks after the initiation of treatment (V1) ctDNA status with treatment outcomes. | npj Precision Oncology

Fig. 3: Association of 4 weeks after the initiation of treatment (V1) ctDNA status with treatment outcomes.

From: Comparative analysis of ctDNA monitoring strategies in advanced NSCLC with MET exon 14 skipping mutations treated with ensartinib

Fig. 3: Association of 4 weeks after the initiation of treatment (V1) ctDNA status with treatment outcomes.

A The venn diagram showing the number of patients with ctDNA positive results detected by the three profiling paradigms at V1. B Longitudinal alterations of ctDNA status during treatment. Kaplan-Meier analysis of progression-free survival (PFS) stratified by ctDNA status for (C) MET-specific alterations, D canonical alterations, and E pan-alterations at V1. F Bar plot comparing the sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of the three profiling paradigms for predicting treatment response at V1.

Back to article page